Amgen’s Phase 3 TEPEZZA OBI Results: Redefining Thyroid Eye Disease Drug Delivery

1. Phase 3 TEPEZZA OBI Trial at a Glance

Amgen reported positive topline Phase 3 results for subcutaneous TEPEZZA (teprotumumab‑trbw) delivered via an on-body injector (OBI) in adults with moderate-to-severe active Thyroid Eye Disease (TED), suggesting a practical alternative to the current intravenous (IV) regimen.[2][3]

Trial design:[2][5]

• Randomized, double-masked, placebo-controlled, parallel-group, multicenter
• Adults with active, moderate-to-severe TED; baseline proptosis ≥3 mm
• TEPEZZA or placebo given subcutaneously via OBI every 2 weeks for 24 weeks (12 doses)

Comparison to approved IV TEPEZZA:[1][5]

• IV: 8 infusions every 3 weeks in infusion centers
• OBI: 12 subcutaneous injections every 2 weeks
• Key shift: IV to subcutaneous, and clinic-based infusions to device-enabled dosing

Endpoints and outcomes:[2][3][5]

• Primary: Proptosis responder rate (≥2‑mm reduction at week 24)
  • TEPEZZA OBI: 76.7% vs placebo: 19.6% (p < 0.0001)
• Key secondary: Mean proptosis change at week 24
  • TEPEZZA OBI: −3.17 mm vs placebo: −0.80 mm (p < 0.0001)

Key takeaway: OBI met its primary and key secondary endpoints, with a proptosis effect size closely mirroring IV TEPEZZA.[2][3]

2. Efficacy, Safety, and Clinical Significance

Clinical relevance of proptosis reduction:[2][4]

• ≥2 mm decrease is typically meaningful, associated with:
  • Less eye bulging and exposure keratopathy
  • Lower need for orbital decompression surgery
• The −3.17 mm mean reduction with OBI aligns well with historical IV TEPEZZA data, supporting “IV-level efficacy.”[3][4]

Secondary efficacy findings:[2][3]

• Statistically significant, clinically meaningful improvements in:
  • Overall response rates
  • Proportion achieving Clinical Activity Score (CAS) 0 or 1
  • Diplopia measures, addressing a major driver of disability and work impact

Patient-reported outcomes (GO‑QoL):[2][3]

• Appearance subscale: Significant improvement, indicating reduced psychosocial burden from facial changes
• Visual functioning subscale: Numerical advantage for OBI but not statistically significant, suggesting potential functional gains needing further evaluation

Safety profile:[2][3][4]

• Overall safety consistent with IV TEPEZZA, important for a route change
• Mild-to-moderate injection-site reactions; none caused treatment interruption or discontinuation
• Most common adverse events (≥10%):
  • Muscle spasms
  • Tinnitus
  • Weight decrease
  • Ear discomfort
  • Nausea
  • Diarrhea
• No new safety signals, supporting feasibility of a subcutaneous, device-enabled strategy.[2][3]

3. From IV to On-Body Injector: What Changes for TED Care?

With efficacy and safety aligned to the IV formulation, the main differentiator for TEPEZZA OBI is its potential to reshape TED care pathways. An OBI-enabled regimen could allow treatment in more flexible settings, potentially including at-home administration under appropriate supervision, rather than anchoring care to infusion centers.[3][5] For patients with visually disabling TED, this may lessen travel demands and cumulative time in clinic.[2][5]

IV TEPEZZA, approved in 2020 as the first and only therapy for TED, has now treated more than 25,000 patients worldwide and is supported by Phase 4 and real-world data, including use in chronic or low‑CAS disease and extended treatment courses.[3][5] TEPEZZA OBI builds on this foundation by modernizing delivery rather than altering the molecular target.

Clinicians will need to weigh practical trade-offs:[1][2][5]

• IV:
  • 8 infusions every 3 weeks
  • Fewer visits, longer chair time
  • Dependence on infusion-center infrastructure
• OBI:
  • 12 subcutaneous doses every 2 weeks
  • More frequent but shorter, more flexible encounters
  • Potential integration into community or home-based care

These differences will influence clinic operations, patient time burden, and adherence. The OBI regimen remains investigational pending regulatory review.[3][5]

The diagram below summarizes the divergent care pathways and their convergence on similar clinical outcomes.

flowchart LR
    title TEPEZZA IV vs OBI Pathways
    A[Eligible TED patient] --> B[Select route]
    B --> C[IV infusions]
    B --> D[OBI injections]
    C --> E[Monitor outcomes]
    D --> E[Monitor outcomes]
    E --> F[Care setting shift]

For clinicians and payers, IV-comparable efficacy with a more flexible delivery mode could encourage earlier TEPEZZA use, alter referral patterns between endocrinologists and ophthalmologists, and inform future health economic models once full cost, utilization, and quality-of-life data are available.[2][3]

Conclusion

Phase 3 results indicate that TEPEZZA delivered via an on-body injector can achieve IV-comparable efficacy in moderate-to-severe active TED, with a 76.7% proptosis responder rate, a −3.17 mm mean proptosis reduction, improvements across key secondary endpoints, and a safety profile aligned with IV TEPEZZA.[2][3][4]

These findings position subcutaneous TEPEZZA as a potentially important new option for a vision-threatening disease with major functional and psychosocial impact. Stakeholders should monitor full data releases and regulatory decisions and begin planning how an on-body, subcutaneous regimen might fit within evolving TED treatment pathways and multidisciplinary guidelines.[2][3]